---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pathophysiology"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pathophysiology. Topics: Disease mechanism: stressors of the RPE, drusen, and complement-mediated inflammation; Ageing changes and extracellular deposits in the outer retina; Complement system: three lines of evidence in geographic atrophy; Complement regulation: CFH binding to C3b and the alternative pathway; 6 further topics. 10 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Disease mechanism: stressors of the RPE, drusen, and complement-mediated inflammation

> “The pathogenesis of GA is multifactorial and is generally thought to be triggered by intrinsic and extrinsic stressors of the poorly regenerative RPE, particularly oxidative stress caused by the high metabolic demand of photoreceptors, photo-oxidation, and environmental stressors such as cigarette smoke.”
> “Components of drusen (cellular debris, lipids, lipoproteins, amyloid deposits) and lipofuscin (by-products of photoreceptor outer-segment degradation, A2E), as well as other products of oxidative stress such as advanced glycation end products, are thought to trigger inflammation via multiple pathways, such as the complement cascade and the NLRP3 inflammasome. When the regulatory components in these pathways are compromised, as is the case with several GA-linked genetic risk factors in the complement cascade, this inflammation can ultimately lead to the retinal cell death characteristic of GA.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

> “The underlying pathophysiology of GA is complex and thought to involve chronic inflammation due to overactivation of the complement system that leads to the loss of photoreceptors, retinal pigment epithelium (RPE), and the underlying choriocapillaris.”

Source: [Bakri et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10408405/)

<a id="topic-2.2.1.4-2"></a>

### Ageing changes and extracellular deposits in the outer retina

> “Aging-related changes cause increasing resistance of blood vessels and reduction of choriocapillaris density, lipid and lipoprotein deposition in the Bruch membrane, and reduction in photoreceptor density.”
> “Extracellular deposits, collectively known as drusen, comprise materials such as lipids, minerals, and proteins and are implicated in the development and progression of AMD.”

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.4-3"></a>

### Complement system: three lines of evidence in geographic atrophy

> “The case for complement cascade dysfunction in AMD is supported by three key lines of evidence. Landmark genome-wide association studies (GWAS) identified AMD-associated variants in complement factor genes, particularly those such as CFH that promote alternative complement pathway termination on host cells.”
> “In addition, patients with GA exhibit alterations in complement cascade components both systemically and locally within the eye. Finally, these observations are supported by preclinical research in vitro and in mice, which have demonstrated that complement dysfunction is associated with GA-like pathology.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

> “Analyses of donor eye tissue demonstrated the presence of complement proteins such as C3 and C5 in drusen of patients with AMD. In addition, post-mortem studies have shown that C5b-9 (membrane attack complex) accumulates in the choriocapillaris and BrM with increasing age and in eyes with AMD”
> “Indeed, a large number of high-risk genetic variants are found in genes encoding complement system regulatory proteins (for example, CFH, CFI, C3 and FB/C2)”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.4-4"></a>

### Complement regulation: CFH binding to C3b and the alternative pathway

> “The CFH gene product is involved in regulation of the complement system through binding to factor C3b.”
> “An alteration of regulation that occurs from modification at the C3b site leads to a defective regulation of the alternative complement pathway and results in an up-regulation of inflammation to host cells that are mediated by the membrane attack complex.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “Each of the CFH Y402H, CFH R1210C, and C3 K155Q variants are predicted to reduce the interaction between CFH and C3b, thus diminishing complement cascade inactivation and potentially increasing feedback amplification of the alternative complement pathway.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="topic-2.2.1.4-5"></a>

### Complement pathways: classical pathway initiation by C1 and convergence at C3 and C5

> “The classical complement pathway is activated when the C1 complex binds specific antigen–antibody complexes, often immunoglobulin M (IgM), IgG3, or IgG1. This induces a conformational change in the C1 complex, allowing it to cleave C4 and C2 to generate the C4bC2b complex. C4bC2b acts as the C3 convertase of the classical pathway, cleaving C3 into C3a and C3b.”
> “The oldest evolutionary signaling pathway of the three, the alternative complement pathway acts both independently of, and as an amplification loop for, the classical and lectin pathways.”
> “The classical, lectin, and alternative complement pathways converge with the cleavage of C3 into C3a and C3b and the subsequent formation of the C5 convertase complexes of C4bC2bC3b (classical, lectin pathways) or C3bC3bBb (alternative complement pathway). These C5 convertase complexes cleave C5 into C5a and C5b, initiating the final steps of the complement cascade.”

Source: [Boyer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5424580/)

<a id="topic-2.2.1.4-6"></a>

### Classical pathway and C1q in geographic atrophy: sponsor-authored review

> “However, the involvement of the different complement pathways (classical, lectin, alternative), and thus the optimal complement inhibition target, has yet to be fully defined. There is evidence that C1q, the initiating molecule of the classical pathway, is a key driver of complement activity in AMD.”
> “Multiple lines of evidence suggest that the classical pathway may be a key initiator of complement activation in GA. First, C1q is present in all layers of the outer retina in GA along with numerous C1q-activating ligands that accumulate throughout disease initiation and progression. Second, C1q and the classical pathway are implicated by retinal pathology in GA and in animal models of GA. Third, in RPE culture models, C1q triggers C5b-9 deposition on basement membrane components and contributes to induction of the inflammasome and cell necrosis. Fourth, inhibition of C1q and downstream C4 is protective in animal models of photoreceptor cell loss. Fifth, C1q accumulates on photoreceptor cell synapses in mice with age and light-induced injury, consistent with the unique role it plays in synapse elimination and neurodegeneration in other disorders.”
> “C1q is highly expressed in infiltrating macrophages within all layers of the outer retina (OPL, POS, RPE, and choroid layers) in GA”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="topic-2.2.1.4-7"></a>

### C1q and photoreceptor synapse elimination: sponsor-authored review

> “Photoreceptor cell stress in GA caused by decline in RPE function and other factors may lead to a process of synapse elimination, neuroinflammation and neuronal loss that is common in multiple neurodegenerative disorders.”
> “In GA, with declining RPE function and neuronal stress, C1q on synapses may activate the classical pathway, and as in other neurodegenerative disorders, result in compromised synapse function and microglial cell recruitment”
> “While blocking downstream components of all three pathways has provided promise in clinical studies, targeting the classical pathway in GA would provide a more selective approach with the potential for increased efficacy and safety.”

Source: [Yednock et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9641935/)

<a id="topic-2.2.1.4-8"></a>

### Preclinical evidence: subretinal macrophage C1q in photo-oxidative retinal degeneration

> “Wild-type (WT), C1qa knockout (C1qa−/−) and mice treated with a C1q inhibitor (ANX-M1; Annexon Biosciences), were exposed to photo-oxidative damage (PD) and were observed for progressive lesion development.”
> “Retinal neutralisation of C1q, using an intravitreally-delivered anti-C1q antibody, reduced the progression of retinal degeneration following PD, while systemic delivery had no effect. Finally, retinal C1q was found to be expressed by subretinal microglia/macrophages located in the outer retina of early AMD donor eyes, and in mouse PD retinas.”
> “Our data implicate subretinal macrophages, C1q and the classical pathway in progressive retinal degeneration.”

Source: [Jiao et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6102844/)

<a id="topic-2.2.1.4-9"></a>

### RPE dysfunction preceding photoreceptor cell death

> “Ultimately, the interplay of the above-described pathological changes including chronic tissue hypoxia owing to choriocapillaris microvasculopathy, chronic inflammation and ROS-mediated oxidative stress may lead to the actual ‘end-stage’ of AMD, which is neurodegeneration, specifically photoreceptor cell death causing irreversible vision loss. In ageing and AMD, rods degenerate ahead of cones”
> “Photoreceptor cell death is presumably directly induced by the breakdown of multiple systems that are crucial for photoreceptor outer segment morphogenesis, phototransduction and metabolic homeostasis. These systems are mainly maintained by the RPE, which, in the course of AMD undergoes degeneration, finally leading to cell death.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.4-10"></a>

### Mechanisms of lesion enlargement distinct from disease onset

> “These findings suggest that biological mechanisms involved in GA enlargement differ at least partially from those underlying its nascence.”
> “Furthermore, in patients with established GA, targeting complement might not be efficacious as other factors and mechanisms have been hypothesized to drive GA enlargement”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
